NewLeaf Symbiotics
Science-based company doing cutting-edge research and product development, using a naturally occurring family of beneficial plant bacteria.
Launch date
Employees
Market cap
-
Enterprise valuation
$180—270m (Dealroom.co estimates Dec 2023.)
Olivette Missouri (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
* | $7.0m | Series A | |
$17.0m | Series B | ||
N/A | $3.6m | Debt | |
$30.0m | Series C | ||
* | $20.0m | Series D | |
$2.0m Valuation: $150m | Series D | ||
N/A | $10.0m | Convertible | |
* | $45.0m | Series D | |
Total Funding | $131m |
Recent News about NewLeaf Symbiotics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by NewLeaf Symbiotics
EditACQUISITION by NewLeaf Symbiotics Dec 2013